Author: "Volterrani, M" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Volterrani, M"' showing total 641 results

Start Over Author "Volterrani, M"

641 results on '"Volterrani, M"'

1. Mental Health among Geriatric Healthcare Workers in Italy during the COVID-19 Pandemic: Results from a National Survey

Author: Ornago, Alice Margherita, Pinardi, E., Zucchelli, A., Trevisan, C., Volterrani, M., Cacciatore, S., Ceolin, C., Landi, F., Trabucchi, M., De Leo, D., Bianchetti, A., and Bellelli, G.
Published: 2023
Full Text: View/download PDF

2. The protective effect of bergamot polyphenolic fraction on reno-cardiac damage induced by DOCA-salt and unilateral renal artery ligation in rats

Author: Carresi, C, primary, Cardamone, A, additional, Coppoletta, A R, additional, Macri, R, additional, Lorenzo, F, additional, Scarano, F, additional, Mollace, R, additional, Ruga, S, additional, Nucera, S, additional, Musolino, V, additional, Gliozzi, M, additional, Palma, E, additional, Muscoli, C, additional, Volterrani, M, additional, and Mollace, V, additional
Published: 2024
Full Text: View/download PDF

3. Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention

Author: Baldassarre, D, Iacoviello, L, Baetta, R, Roncaglioni, M, Condorelli, G, Remuzzi, G, Gensini, G, Frati, L, Ricciardi, W, Conaldi, P, Uccelli, A, Blandini, F, Bosari, S, Scambia, G, Fini, M, Di Malta, A, Amato, M, Veglia, F, Bonomi, A, Klersy, C, Colazzo, F, Pengo, M, Gorini, F, Auteri, L, Ferrante, G, Baviera, M, Ambrosio, G, Catapano, A, Gialluisi, A, Malavazos, A, Castelvecchio, S, Corsi-Romanelli, M, Cardani, R, La Rovere, M, Agnese, V, Pane, B, Prati, D, Spinardi, L, Liuzzo, G, Arbustini, E, Volterrani, M, Visconti, M, Werba, J, Genovese, S, Bilo, G, Invitti, C, Di Blasio, A, Lombardi, C, Faini, A, Rosa, D, Ojeda-Fernandez, L, Foresta, A, De Curtis, A, Di Castelnuovo, A, Scalvini, S, Pierobon, A, Gorini, A, Valenti, L, Luzi, L, Racca, A, Bandi, M, Tremoli, E, Menicanti, L, Parati, G, Pompilio, G, Colombo, G, Vavassori, C, Biondi, M, Frigerio, B, Ravani, A, Sansaro, D, Coggi, D, Romandini, A, Giroli, M, Giuliani, M, Bonmi, A, Rondinelli, M, Trudu, C, Cinieri, C, Monturano, M, Colazo, F, Inviti, C, Di Blasi, A, Torlasco, C, Gilardini, L, Soranna, D, Zambon, A, Perger, E, Zanotti, L, Badano, L, Cova, L, Gentilini, D, Grappiolo, L, Condoreli, G, Ferante, G, Papa, L, Savevski, V, Ieva, F, Romano, I, Remzzi, G, Ojeda, L, Clerici, F, Palumbo, A, Genini, G, Catpano, A, Mattioli, R, Longhi, E, Mantovani, L, Madotto, F, Bonaccio, M, Gianfagna, F, Ghulam, A, Magnacca, S, Noro, F, Costanzo, S, Esposito, S, Orlandi, S, Persichillo, M, Bracone, F, Panzera, T, Ruggiero, E, Parisi, R, Franciosa, S, Morelli, M, De Rita, F, Cerletti, C, de Gaetano, G, Donati, M, Mencanti, L, Romanelli, M, Cerri, A, Dubini, C, Trevisan, M, Renna, L, Milani, V, Boveri, S, Giubbilini, P, Ramputi, L, Baroni, I, De Angeli, G, Riciardi, W, Olmetti, F, Bussotti, M, Gaetano, C, Baiardi, P, Bachetti, T, Balbi, M, Comini, L, Lorenzoni, M, Olivares, A, Traversi, E, Garre, C, Sideri, R, Clemenza, F, Gentile, G, Caruana, G, Cuscino, N, Di Gesaro, G, Greco, A, Loddo, I, Tuzzolino, F, Ucelli, A, Palombo, D, Spinella, G, Mozzetta, G, Ameri, P, Zoppoli, G, Finotello, A, Porto, I, Pratesi, G, Bladini, F, Spnardi, L, Clerici, M, Pelusi, S, Bianco, C, Carpani, R, Periti, G, Margarita, S, Lanza, G, Severino, A, Pedicino, D, D'Amario, D, D'Aiello, A, Vinci, R, Bonanni, A, Brecciaroli, M, Filomia, S, Pastorino, R, Boccia, S, Urbani, A, Sanguinetti, M, Santoliquido, A, Proto, L, Tarquini, D, Grimaldi, M, Leonardi, S, Elia, A, Currao, A, Urtis, M, Di Toro, A, Giuliani, L, Caminiti, G, Marcolongo, F, Sposato, B, Guadagni, F, Morsella, V, Marziale, A, Protti, G, Baldassarre D., Iacoviello L., Baetta R., Roncaglioni M. C., Condorelli G., Remuzzi G., Gensini G., Frati L., Ricciardi W., Conaldi P. G., Uccelli A., Blandini F., Bosari S., Scambia G., Fini M., Di Malta A., Amato M., Veglia F., Bonomi A., Klersy C., Colazzo F., Pengo M., Gorini F., Auteri L., Ferrante G., Baviera M., Ambrosio G., Catapano A., Gialluisi A., Malavazos A. E., Castelvecchio S., Corsi-Romanelli M. M., Cardani R., La Rovere M. T., Agnese V., Pane B., Prati D., Spinardi L., Liuzzo G., Arbustini E., Volterrani M., Visconti M., Werba J. P., Genovese S., Bilo G., Invitti C., Di Blasio A., Lombardi C., Faini A., Rosa D., Ojeda-Fernandez L., Foresta A., De Curtis A., Di Castelnuovo A., Scalvini S., Pierobon A., Gorini A., Valenti L., Luzi L., Racca A., Bandi M., Tremoli E., Menicanti L., Parati G., Pompilio G., Colombo G., Vavassori C., Biondi M. L., Frigerio B., Ravani A., Sansaro D., Coggi D., Romandini A., Giroli M., Giuliani M., Bonmi A., Rondinelli M., Trudu C., Cinieri C., Monturano M., Colazo F., Inviti C., Di Blasi A., Torlasco C., Gilardini L., Soranna D., Zambon A., Perger E., Zanotti L., Badano L., Cova L., Gentilini D., Grappiolo L., Condoreli G., Ferante G., Papa L., Savevski V., Ieva F., Romano I., Remzzi G., Ojeda L., Clerici F., Palumbo A., Genini G. F., Catpano A., Mattioli R., Longhi E., Mantovani L. G., Madotto F., Bonaccio M., Gianfagna F., Ghulam A., Magnacca S., Noro F., Costanzo S., Esposito S., Orlandi S., Persichillo M., Bracone F., Panzera T., Ruggiero E., Parisi R., Franciosa S., Morelli M., De Rita F., Cerletti C., de Gaetano G., Donati M. B., Mencanti L., Romanelli M. M. C., Cerri A., Dubini C., Trevisan M. B., Renna L. V., Milani V., Boveri S., Giubbilini P., Ramputi L., Baroni I., De Angeli G., Riciardi W., Olmetti F., Bussotti M., Gaetano C., Baiardi P., Bachetti T., Balbi M., Comini L., Lorenzoni M., Olivares A., Traversi E., Garre C., Sideri R., Clemenza F., Gentile G., Caruana G., Cuscino N., Di Gesaro G., Greco A., Loddo I., Tuzzolino F., Ucelli A., Palombo D., Spinella G., Mozzetta G., Ameri P., Zoppoli G., Finotello A., Porto I., Pratesi G., Bladini F., Spnardi L., Clerici M., Pelusi S., Bianco C., Carpani R., Periti G., Margarita S., Lanza G. A., Severino A., Pedicino D., D'Amario D., D'Aiello A., Vinci R., Bonanni A., Brecciaroli M., Filomia S., Pastorino R., Boccia S., Urbani A., Sanguinetti M., Santoliquido A., Proto L., Tarquini D., Grimaldi M. C., Leonardi S., Elia A., Currao A., Urtis M., Di Toro A., Giuliani L., Caminiti G., Marcolongo F., Sposato B., Guadagni F., Morsella V., Marziale A., Protti G., Baldassarre, D, Iacoviello, L, Baetta, R, Roncaglioni, M, Condorelli, G, Remuzzi, G, Gensini, G, Frati, L, Ricciardi, W, Conaldi, P, Uccelli, A, Blandini, F, Bosari, S, Scambia, G, Fini, M, Di Malta, A, Amato, M, Veglia, F, Bonomi, A, Klersy, C, Colazzo, F, Pengo, M, Gorini, F, Auteri, L, Ferrante, G, Baviera, M, Ambrosio, G, Catapano, A, Gialluisi, A, Malavazos, A, Castelvecchio, S, Corsi-Romanelli, M, Cardani, R, La Rovere, M, Agnese, V, Pane, B, Prati, D, Spinardi, L, Liuzzo, G, Arbustini, E, Volterrani, M, Visconti, M, Werba, J, Genovese, S, Bilo, G, Invitti, C, Di Blasio, A, Lombardi, C, Faini, A, Rosa, D, Ojeda-Fernandez, L, Foresta, A, De Curtis, A, Di Castelnuovo, A, Scalvini, S, Pierobon, A, Gorini, A, Valenti, L, Luzi, L, Racca, A, Bandi, M, Tremoli, E, Menicanti, L, Parati, G, Pompilio, G, Colombo, G, Vavassori, C, Biondi, M, Frigerio, B, Ravani, A, Sansaro, D, Coggi, D, Romandini, A, Giroli, M, Giuliani, M, Bonmi, A, Rondinelli, M, Trudu, C, Cinieri, C, Monturano, M, Colazo, F, Inviti, C, Di Blasi, A, Torlasco, C, Gilardini, L, Soranna, D, Zambon, A, Perger, E, Zanotti, L, Badano, L, Cova, L, Gentilini, D, Grappiolo, L, Condoreli, G, Ferante, G, Papa, L, Savevski, V, Ieva, F, Romano, I, Remzzi, G, Ojeda, L, Clerici, F, Palumbo, A, Genini, G, Catpano, A, Mattioli, R, Longhi, E, Mantovani, L, Madotto, F, Bonaccio, M, Gianfagna, F, Ghulam, A, Magnacca, S, Noro, F, Costanzo, S, Esposito, S, Orlandi, S, Persichillo, M, Bracone, F, Panzera, T, Ruggiero, E, Parisi, R, Franciosa, S, Morelli, M, De Rita, F, Cerletti, C, de Gaetano, G, Donati, M, Mencanti, L, Romanelli, M, Cerri, A, Dubini, C, Trevisan, M, Renna, L, Milani, V, Boveri, S, Giubbilini, P, Ramputi, L, Baroni, I, De Angeli, G, Riciardi, W, Olmetti, F, Bussotti, M, Gaetano, C, Baiardi, P, Bachetti, T, Balbi, M, Comini, L, Lorenzoni, M, Olivares, A, Traversi, E, Garre, C, Sideri, R, Clemenza, F, Gentile, G, Caruana, G, Cuscino, N, Di Gesaro, G, Greco, A, Loddo, I, Tuzzolino, F, Ucelli, A, Palombo, D, Spinella, G, Mozzetta, G, Ameri, P, Zoppoli, G, Finotello, A, Porto, I, Pratesi, G, Bladini, F, Spnardi, L, Clerici, M, Pelusi, S, Bianco, C, Carpani, R, Periti, G, Margarita, S, Lanza, G, Severino, A, Pedicino, D, D'Amario, D, D'Aiello, A, Vinci, R, Bonanni, A, Brecciaroli, M, Filomia, S, Pastorino, R, Boccia, S, Urbani, A, Sanguinetti, M, Santoliquido, A, Proto, L, Tarquini, D, Grimaldi, M, Leonardi, S, Elia, A, Currao, A, Urtis, M, Di Toro, A, Giuliani, L, Caminiti, G, Marcolongo, F, Sposato, B, Guadagni, F, Morsella, V, Marziale, A, Protti, G, Baldassarre D., Iacoviello L., Baetta R., Roncaglioni M. C., Condorelli G., Remuzzi G., Gensini G., Frati L., Ricciardi W., Conaldi P. G., Uccelli A., Blandini F., Bosari S., Scambia G., Fini M., Di Malta A., Amato M., Veglia F., Bonomi A., Klersy C., Colazzo F., Pengo M., Gorini F., Auteri L., Ferrante G., Baviera M., Ambrosio G., Catapano A., Gialluisi A., Malavazos A. E., Castelvecchio S., Corsi-Romanelli M. M., Cardani R., La Rovere M. T., Agnese V., Pane B., Prati D., Spinardi L., Liuzzo G., Arbustini E., Volterrani M., Visconti M., Werba J. P., Genovese S., Bilo G., Invitti C., Di Blasio A., Lombardi C., Faini A., Rosa D., Ojeda-Fernandez L., Foresta A., De Curtis A., Di Castelnuovo A., Scalvini S., Pierobon A., Gorini A., Valenti L., Luzi L., Racca A., Bandi M., Tremoli E., Menicanti L., Parati G., Pompilio G., Colombo G., Vavassori C., Biondi M. L., Frigerio B., Ravani A., Sansaro D., Coggi D., Romandini A., Giroli M., Giuliani M., Bonmi A., Rondinelli M., Trudu C., Cinieri C., Monturano M., Colazo F., Inviti C., Di Blasi A., Torlasco C., Gilardini L., Soranna D., Zambon A., Perger E., Zanotti L., Badano L., Cova L., Gentilini D., Grappiolo L., Condoreli G., Ferante G., Papa L., Savevski V., Ieva F., Romano I., Remzzi G., Ojeda L., Clerici F., Palumbo A., Genini G. F., Catpano A., Mattioli R., Longhi E., Mantovani L. G., Madotto F., Bonaccio M., Gianfagna F., Ghulam A., Magnacca S., Noro F., Costanzo S., Esposito S., Orlandi S., Persichillo M., Bracone F., Panzera T., Ruggiero E., Parisi R., Franciosa S., Morelli M., De Rita F., Cerletti C., de Gaetano G., Donati M. B., Mencanti L., Romanelli M. M. C., Cerri A., Dubini C., Trevisan M. B., Renna L. V., Milani V., Boveri S., Giubbilini P., Ramputi L., Baroni I., De Angeli G., Riciardi W., Olmetti F., Bussotti M., Gaetano C., Baiardi P., Bachetti T., Balbi M., Comini L., Lorenzoni M., Olivares A., Traversi E., Garre C., Sideri R., Clemenza F., Gentile G., Caruana G., Cuscino N., Di Gesaro G., Greco A., Loddo I., Tuzzolino F., Ucelli A., Palombo D., Spinella G., Mozzetta G., Ameri P., Zoppoli G., Finotello A., Porto I., Pratesi G., Bladini F., Spnardi L., Clerici M., Pelusi S., Bianco C., Carpani R., Periti G., Margarita S., Lanza G. A., Severino A., Pedicino D., D'Amario D., D'Aiello A., Vinci R., Bonanni A., Brecciaroli M., Filomia S., Pastorino R., Boccia S., Urbani A., Sanguinetti M., Santoliquido A., Proto L., Tarquini D., Grimaldi M. C., Leonardi S., Elia A., Currao A., Urtis M., Di Toro A., Giuliani L., Caminiti G., Marcolongo F., Sposato B., Guadagni F., Morsella V., Marziale A., and Protti G.
Abstract: Introduction Prevention of cardiovascular disease (CVD) is of key importance in reducing morbidity, disability and mortality worldwide. Observational studies suggest that digital health interventions can be an effective strategy to reduce cardiovascular (CV) risk. However, evidence from large randomised clinical trials is lacking. Methods and analysis The CV-PREVITAL study is a multicentre, prospective, randomised, controlled, open-label interventional trial designed to compare the effectiveness of an educational and motivational mobile health (mHealth) intervention versus usual care in reducing CV risk. The intervention aims at improving diet, physical activity, sleep quality, psycho-behavioural aspects, as well as promoting smoking cessation and adherence to pharmacological treatment for CV risk factors. The trial aims to enrol approximately 80 000 subjects without overt CVDs referring to general practitioners' offices, community pharmacies or clinics of Scientific Institute for Research, Hospitalization and Health Care (Italian acronym IRCCS) affiliated with the Italian Cardiology Network. All participants are evaluated at baseline and after 12 months to assess the effectiveness of the intervention on short-term endpoints, namely improvement in CV risk score and reduction of major CV risk factors. Beyond the funded life of the study, a long-term (7 years) follow-up is also planned to assess the effectiveness of the intervention on the incidence of major adverse CV events. A series of ancillary studies designed to evaluate the effect of the mHealth intervention on additional risk biomarkers are also performed. Ethics and dissemination This study received ethics approval from the ethics committee of the coordinating centre (Monzino Cardiology Center; R1256/20-CCM 1319) and from all other relevant IRBs and ethics committees. Findings are disseminated through scientific meetings and peer-reviewed journals and via social media. Partners are informed about the study's
Published: 2023

4. Mental Health among Geriatric Healthcare Workers in Italy during the COVID-19 Pandemic: Results from a National Survey

Author: Ornago, A, Pinardi, E, Zucchelli, A, Trevisan, C, Volterrani, M, Cacciatore, S, Ceolin, C, Landi, F, Trabucchi, M, De Leo, D, Bianchetti, A, Bellelli, G, Ornago A. M., Pinardi E., Zucchelli A., Trevisan C., Volterrani M., Cacciatore S., Ceolin C., Landi F., Trabucchi M., De Leo D., Bianchetti A., Bellelli G., Ornago, A, Pinardi, E, Zucchelli, A, Trevisan, C, Volterrani, M, Cacciatore, S, Ceolin, C, Landi, F, Trabucchi, M, De Leo, D, Bianchetti, A, Bellelli, G, Ornago A. M., Pinardi E., Zucchelli A., Trevisan C., Volterrani M., Cacciatore S., Ceolin C., Landi F., Trabucchi M., De Leo D., Bianchetti A., and Bellelli G.
Abstract: Objectives: This study aimed to investigate the psychological impact of the COVID-19 pandemic on healthcare workers (HCWs) in geriatric settings. Design: Online cross-sectional survey. Settings and Participants: 394 geriatric HCWs in Italy. Measurements: The survey was developed by a multidisciplinary team and disseminated in April 2022 to the members of two geriatric scientific societies (Italian Society of Geriatrics and Gerontology and Italian Association of Psychogeriatrics). The survey examined the experiences related to the COVID-19 pandemic, as well as psychological burden and support. Work-related anxiety and distress related to the pandemic were studied using the SAVE-9 scale (Stress and Anxiety to Viral Epidemics). Results: Three hundred sixty-four participants (92.4%) changed their job activity during the pandemic and about half (50.9%) failed to cope with this change, 58 (14.7%) had increased work-related anxiety, and 39 (9.9%) work-related stress levels. Three hundred forty (86.3%) participants reported acute stress reaction symptoms, including irritability, depressed mood, headache, anxiety, and insomnia, and 262 (66.5%) required psychological support, mainly from friends/relatives (57.9%) and/or colleagues (32.5%). Furthermore, 342 participants (86.8%) recognized they would benefit from informal and formal psychological support in case of future similar emergencies. Conclusions: This study highlights the high psychological burden experienced by geriatric HCWs in Italy during the COVID-19 pandemic and emphasizes the need for supportive interventions.
Published: 2023

5. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)

Author: Lee, Randall, Anker, SD, Coats, AJS, Cristian, G, Dragomir, D, Pusineri, E, Piredda, M, Bettari, L, Dowling, R, Volterrani, M, and Kirwan, BA
Abstract: © 2015 The Author 2015.Aims AUGMENT-HF was an international, multi-centre, prospective, randomized, controlled trial to evaluate the benefits and safety of a novel method of left ventricular (LV) modification with alginate-hydrogel. Methods Alginate-hydrog
Published: 2015

6. Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study)

Author: Iorio, A, Lombardi, C, Specchia, C, Merlo, M, Nuzzi, V, Ferraro, I, Peveri, G, Oriecuia, C, Pozzi, A, Inciardi, R, Carubelli, V, Bellasi, A, Canale, C, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Giovinazzo, S, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Provenzale, G, Sarullo, F, Tomasoni, D, Ameri, P, Gnecchi, M, Leonardi, S, Agostoni, P, Carugo, S, Danzi, G, Guazzi, M, La Rovere, M, Mortara, A, Piepoli, M, Porto, I, Volterrani, M, Sinagra, G, Senni, M, Metra, M, Iorio A., Lombardi C. M., Specchia C., Merlo M., Nuzzi V., Ferraro I., Peveri G., Oriecuia C., Pozzi A., Inciardi R. M., Carubelli V., Bellasi A., Canale C., Camporotondo R., Catagnano F., Dalla Vecchia L., Giovinazzo S., Maccagni G., Mapelli M., Margonato D., Monzo L., Provenzale G., Sarullo F., Tomasoni D., Ameri P., Gnecchi M., Leonardi S., Agostoni P., Carugo S., Danzi G. B., Guazzi M., La Rovere M. T., Mortara A., Piepoli M., Porto I., Volterrani M., Sinagra G., Senni M., Metra M., Iorio, A, Lombardi, C, Specchia, C, Merlo, M, Nuzzi, V, Ferraro, I, Peveri, G, Oriecuia, C, Pozzi, A, Inciardi, R, Carubelli, V, Bellasi, A, Canale, C, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Giovinazzo, S, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Provenzale, G, Sarullo, F, Tomasoni, D, Ameri, P, Gnecchi, M, Leonardi, S, Agostoni, P, Carugo, S, Danzi, G, Guazzi, M, La Rovere, M, Mortara, A, Piepoli, M, Porto, I, Volterrani, M, Sinagra, G, Senni, M, Metra, M, Iorio A., Lombardi C. M., Specchia C., Merlo M., Nuzzi V., Ferraro I., Peveri G., Oriecuia C., Pozzi A., Inciardi R. M., Carubelli V., Bellasi A., Canale C., Camporotondo R., Catagnano F., Dalla Vecchia L., Giovinazzo S., Maccagni G., Mapelli M., Margonato D., Monzo L., Provenzale G., Sarullo F., Tomasoni D., Ameri P., Gnecchi M., Leonardi S., Agostoni P., Carugo S., Danzi G. B., Guazzi M., La Rovere M. T., Mortara A., Piepoli M., Porto I., Volterrani M., Sinagra G., Senni M., and Metra M.
Abstract: Data concerning the combined prognostic role of natriuretic peptide (NP) and troponin in patients with COVID-19 are lacking. The aim of the study is to evaluate the combined prognostic value of NPs and troponin in hospitalized COVID-19 patients. From March 1, 2020 to April 9, 2020, consecutive patients with COVID-19 and available data on cardiac biomarkers at admission were recruited. Patients admitted for acute coronary syndrome were excluded. Troponin levels were defined as elevated when greater than the 99th percentile of normal values. NPs were considered elevated if above the limit for ruling in acute heart failure (HF). A total of 341 patients were included in this study, mean age 68 ± 13 years, 72% were men. During a median follow-up period of 14 days, 81 patients (24%) died. In the Cox regression analysis, patients with elevated both NPs and troponin levels had higher risk of death compared with those with normal levels of both (hazard ratio 2.94; 95% confidence interval 1.31 to 6.64; p = 0.009), and this remained significant after adjustment for age, gender, oxygen saturation, HF history, and chronic kidney disease. Interestingly, NPs provided risk stratification also in patients with normal troponin values (hazard ratio 2.86; 95% confidence interval 1.21 to 6.72; p = 0.016 with high NPs levels). These data show the combined prognostic role of troponin and NPs in COVID-19 patients. NPs value may be helpful in identifying patients with a worse prognosis among those with normal troponin values. Further, NPs’ cut-point used for diagnosis of acute HF has a predictive role in patients with COVID-19.
Published: 2022

7. Sex-related differences in patients with coronavirus disease 2019: Results of the Cardio-COVID-Italy multicentre study

Author: Lombardi, C, Specchia, C, Conforti, F, Rovere, M, Carubelli, V, Agostoni, P, Carugo, S, Danzi, G, Guazzi, M, Mortara, A, Piepoli, M, Porto, I, Sinagra, G, Volterrani, M, Ameri, P, Gnecchi, M, Leonardi, S, Merlo, M, Iorio, A, Bellasi, A, Canale, C, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Di Pasquale, M, Giovinazzo, S, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Nuzzi, V, Oriecuia, C, Pala, L, Peveri, G, Pozzi, A, Provenzale, G, Sarullo, F, Adamo, M, Tomasoni, D, Inciardi, R, Senni, M, Metra, M, Lombardi C. M., Specchia C., Conforti F., Rovere M. T. L., Carubelli V., Agostoni P., Carugo S., Danzi G. B., Guazzi M., Mortara A., Piepoli M., Porto I., Sinagra G., Volterrani M., Ameri P., Gnecchi M., Leonardi S., Merlo M., Iorio A., Bellasi A., Canale C., Camporotondo R., Catagnano F., Dalla Vecchia L. A., Di Pasquale M., Giovinazzo S., Maccagni G., Mapelli M., Margonato D., Monzo L., Nuzzi V., Oriecuia C., Pala L., Peveri G., Pozzi A., Provenzale G., Sarullo F., Adamo M., Tomasoni D., Inciardi R. M., Senni M., Metra M., Lombardi, C, Specchia, C, Conforti, F, Rovere, M, Carubelli, V, Agostoni, P, Carugo, S, Danzi, G, Guazzi, M, Mortara, A, Piepoli, M, Porto, I, Sinagra, G, Volterrani, M, Ameri, P, Gnecchi, M, Leonardi, S, Merlo, M, Iorio, A, Bellasi, A, Canale, C, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Di Pasquale, M, Giovinazzo, S, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Nuzzi, V, Oriecuia, C, Pala, L, Peveri, G, Pozzi, A, Provenzale, G, Sarullo, F, Adamo, M, Tomasoni, D, Inciardi, R, Senni, M, Metra, M, Lombardi C. M., Specchia C., Conforti F., Rovere M. T. L., Carubelli V., Agostoni P., Carugo S., Danzi G. B., Guazzi M., Mortara A., Piepoli M., Porto I., Sinagra G., Volterrani M., Ameri P., Gnecchi M., Leonardi S., Merlo M., Iorio A., Bellasi A., Canale C., Camporotondo R., Catagnano F., Dalla Vecchia L. A., Di Pasquale M., Giovinazzo S., Maccagni G., Mapelli M., Margonato D., Monzo L., Nuzzi V., Oriecuia C., Pala L., Peveri G., Pozzi A., Provenzale G., Sarullo F., Adamo M., Tomasoni D., Inciardi R. M., Senni M., and Metra M.
Abstract: IntroductionThe role of sex compared to comorbidities and other prognostic variables in patients with coronavirus disease (COVID-19) is unclear.MethodsThis is a retrospective observational study on patients with COVID-19 infection, referred to 13 cardiology units. The primary objective was to assess the difference in risk of death between the sexes. The secondary objective was to explore sex-based heterogeneity in the association between demographic, clinical and laboratory variables, and patients' risk of death.ResultsSeven hundred and one patients were included: 214 (30.5%) women and 487 (69.5%) men. During a median follow-up of 15-days, deaths occurred in 39 (18.2%) women and 126 (25.9%) men. In a multivariable Cox regression model, men had a nonsignificantly higher risk of death vs. women (P = 0.07).The risk of death was more than double in men with a low lymphocytes count as compared with men with a high lymphocytes count [overall survival hazard ratio (OS-HR) 2.56, 95% confidence interval (CI) 1.72-3.81]. In contrast, lymphocytes count was not related to death in women (P=0.03).Platelets count was associated with better outcome in men (OS-HR for increase of 50-×-103units: 0.88 95% CI 0.78-1.00) but not in women. The strength of association between higher PaO2/FiO2ratio and lower risk of death was larger in women (OS-HR for increase of 50-mmHg/%: 0.72, 95% CI 0.59-0.89) vs. men (OS-HR: 0.88, 95% CI 0.80-0.98; P-=-0.05).ConclusionsPatients' sex is a relevant variable that should be taken into account when evaluating risk of death from COVID-19. There is a sex-based heterogeneity in the association between baseline variables and patients' risk of death.
Published: 2022

8. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry

Author: Bossone, E., Arcopinto, M., Iacoviello, M., Triggiani, V., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Sciacqua, A., Perrone-Filardi, P., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., De Giorgi, A., Monte, I., Puzzo, A., Ballotta, A., Caliendo, L., D’Assante, R., Marra, A. M., Salzano, A., Suzuki, T., Cittadini, A., and On behalf of TOSCA Investigators
Published: 2018
Full Text: View/download PDF

9. Effects of concurrent exercise training on blood pressure variability and values are blunted in subjects with non-dipping blood pressure nocturnal pattern

Author: Caminiti, G, primary, Sposato, B, additional, Iellamo, F, additional, Perrone, M A, additional, Di Carlo, R, additional, Cascelli, G, additional, Franchini, A, additional, and Volterrani, M, additional
Published: 2023
Full Text: View/download PDF

10. P288 TREATMENT OF HEART FAILURE IN CLINICAL PRACTICE: NON–INTERVENTIONAL OBSERVATIONAL STUDY ON PATIENTS WITH HEART FAILURE TREATED WITH DAPAGLIFLOZIN (EVOLUTION–HF ITALY)

Author: Orso, F, primary, Ameri, P, additional, Carugo, S, additional, Di Lenarda, A, additional, Iacoviello, M, additional, Indolfi, C, additional, Mortara, A, additional, Perrone Filardi, P, additional, Ungar, A, additional, Volpe, M, additional, Volterrani, M, additional, Granelli, V, additional, Mastromauro, F, additional, Pluchinotta, F, additional, Gnesi, M, additional, and Rosano, G, additional
Published: 2023
Full Text: View/download PDF

11. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

Author: Rosano, G, Jankowska, E, Ray, R, Metra, M, Abdelhamid, M, Adamopoulos, S, Anker, S, Bayes-Genis, A, Belenkov, Y, Gal, T, Böhm, M, Chioncel, O, Cohen-Solal, A, Farmakis, D, Filippatos, G, González, A, Gustafsson, F, Hill, L, Jaarsma, T, Jouhra, F, Lainscak, M, Lambrinou, E, Lopatin, Y, Lund, L, Milicic, D, Moura, B, Mullens, W, Piepoli, M, Ponikowski, P, Rakisheva, A, Ristic, A, Savarese, G, Seferovic, P, Senni, M, Thum, T, Tocchetti, C, Van Linthout, S, Volterrani, M, Coats, A, Rosano G, Jankowska EA, Ray R, Metra M, Abdelhamid M, Adamopoulos S, Anker SD, Bayes-Genis A, Belenkov Y, Gal TB, Böhm M, Chioncel O, Cohen-Solal A, Farmakis D, Filippatos G, González A, Gustafsson F, Hill L, Jaarsma T, Jouhra F, Lainscak M, Lambrinou E, Lopatin Y, Lund LH, Milicic D, Moura B, Mullens W, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Seferovic P, Senni M, Thum T, Tocchetti CG, Van Linthout S, Volterrani M, Coats AJS, Rosano, G, Jankowska, E, Ray, R, Metra, M, Abdelhamid, M, Adamopoulos, S, Anker, S, Bayes-Genis, A, Belenkov, Y, Gal, T, Böhm, M, Chioncel, O, Cohen-Solal, A, Farmakis, D, Filippatos, G, González, A, Gustafsson, F, Hill, L, Jaarsma, T, Jouhra, F, Lainscak, M, Lambrinou, E, Lopatin, Y, Lund, L, Milicic, D, Moura, B, Mullens, W, Piepoli, M, Ponikowski, P, Rakisheva, A, Ristic, A, Savarese, G, Seferovic, P, Senni, M, Thum, T, Tocchetti, C, Van Linthout, S, Volterrani, M, Coats, A, Rosano G, Jankowska EA, Ray R, Metra M, Abdelhamid M, Adamopoulos S, Anker SD, Bayes-Genis A, Belenkov Y, Gal TB, Böhm M, Chioncel O, Cohen-Solal A, Farmakis D, Filippatos G, González A, Gustafsson F, Hill L, Jaarsma T, Jouhra F, Lainscak M, Lambrinou E, Lopatin Y, Lund LH, Milicic D, Moura B, Mullens W, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Seferovic P, Senni M, Thum T, Tocchetti CG, Van Linthout S, Volterrani M, and Coats AJS
Abstract: Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.
Published: 2021

12. Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: Results of the Cardio-COVID-Italy multicentre study

Author: Paris, S, Inciardi, R, Lombardi, C, Tomasoni, D, Ameri, P, Carubelli, V, Agostoni, P, Canale, C, Carugo, S, Danzi, G, Di Pasquale, M, Sarullo, F, La Rovere, M, Mortara, A, Piepoli, M, Porto, I, Sinagra, G, Volterrani, M, Gnecchi, M, Leonardi, S, Merlo, M, Iorio, A, Giovinazzo, S, Bellasi, A, Zaccone, G, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Nuzzi, V, Pozzi, A, Provenzale, G, Specchia, C, Tedino, C, Guazzi, M, Senni, M, Metra, M, Paris S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V, Agostoni P, Canale C, Carugo S, Danzi G, Di Pasquale M, Sarullo F, La Rovere MT, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, Gnecchi M, Leonardi S, Merlo M, Iorio A, Giovinazzo S, Bellasi A, Zaccone G, Camporotondo R, Catagnano F, Dalla Vecchia L, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Pozzi A, Provenzale G, Specchia C, Tedino C, Guazzi M, Senni M, Metra M, Paris, S, Inciardi, R, Lombardi, C, Tomasoni, D, Ameri, P, Carubelli, V, Agostoni, P, Canale, C, Carugo, S, Danzi, G, Di Pasquale, M, Sarullo, F, La Rovere, M, Mortara, A, Piepoli, M, Porto, I, Sinagra, G, Volterrani, M, Gnecchi, M, Leonardi, S, Merlo, M, Iorio, A, Giovinazzo, S, Bellasi, A, Zaccone, G, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Nuzzi, V, Pozzi, A, Provenzale, G, Specchia, C, Tedino, C, Guazzi, M, Senni, M, Metra, M, Paris S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V, Agostoni P, Canale C, Carugo S, Danzi G, Di Pasquale M, Sarullo F, La Rovere MT, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, Gnecchi M, Leonardi S, Merlo M, Iorio A, Giovinazzo S, Bellasi A, Zaccone G, Camporotondo R, Catagnano F, Dalla Vecchia L, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Pozzi A, Provenzale G, Specchia C, Tedino C, Guazzi M, Senni M, and Metra M
Abstract: Aims: To assess the clinical relevance of a history of atrial fibrillation (AF) in hospitalized patients with coronavirus disease 2019 (COVID-19). Methods and results: We enrolled 696 consecutive patients (mean age 67.4 ± 13.2 years, 69.7% males) admitted for COVID-19 in 13 Italian cardiology centres between 1 March and 9 April 2020. One hundred and six patients (15%) had a history of AF and the median hospitalization length was 14 days (interquartile range 9-24). Patients with a history of AF were older and with a higher burden of cardiovascular risk factors. Compared to patients without AF, they showed a higher rate of in-hospital death (38.7% vs. 20.8%; P < 0.001). History of AF was associated with an increased risk of death after adjustment for clinical confounders related to COVID-19 severity and cardiovascular comorbidities, including history of heart failure (HF) and increased plasma troponin [adjusted hazard ratio (HR): 1.73; 95% confidence interval (CI) 1.06-2.84; P = 0.029]. Patients with a history of AF also had more in-hospital clinical events including new-onset AF (36.8% vs. 7.9%; P < 0.001), acute HF (25.3% vs. 6.3%; P < 0.001), and multiorgan failure (13.9% vs. 5.8%; P = 0.010). The association between AF and worse outcome was not modified by previous or concomitant use of anticoagulants or steroid therapy (P for interaction >0.05 for both) and was not related to stroke or bleeding events. Conclusion: Among hospitalized patients with COVID-19, a history of AF contributes to worse clinical course with a higher mortality and in-hospital events including new-onset AF, acute HF, and multiorgan failure. The mortality risk remains significant after adjustment for variables associated with COVID-19 severity and comorbidities.
Published: 2021

13. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study

Author: Pagnesi, M, Inciardi, R, Lombardi, C, Agostoni, P, Ameri, P, Barbieri, L, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Dalla Vecchia, L, Danzi, G, Di Pasquale, M, Gaudenzi, M, Giovinazzo, S, Gnecchi, M, Guazzi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Sarullo, F, Sinagra, G, Tedino, C, Tomasoni, D, Volterrani, M, Zaccone, G, Senni, M, Metra, M, Pagnesi M, Inciardi RM, Lombardi CM, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, Gnecchi M, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Senni M, Metra M, Pagnesi, M, Inciardi, R, Lombardi, C, Agostoni, P, Ameri, P, Barbieri, L, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Dalla Vecchia, L, Danzi, G, Di Pasquale, M, Gaudenzi, M, Giovinazzo, S, Gnecchi, M, Guazzi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Sarullo, F, Sinagra, G, Tedino, C, Tomasoni, D, Volterrani, M, Zaccone, G, Senni, M, Metra, M, Pagnesi M, Inciardi RM, Lombardi CM, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, Gnecchi M, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Senni M, and Metra M
Abstract: Background: Glucocorticoid therapy has emerged as an effective therapeutic option in hospitalized patients with coronavirus disease 2019 (COVID-19). This study aimed to focus on the impact of relevant clinical and laboratory factors on the protective effect of glucocorticoids on mortality. Methods: A sub-analysis was performed of the multicenter Cardio-COVID-Italy registry, enrolling consecutive patients with COVID-19 admitted to 13 Italian cardiology units between 01 March 2020 and 09 April 2020. The primary endpoint was in-hospital mortality. Results: A total of 706 COVID-19 patients were included (349 treated with glucocorticoids, 357 not treated with glucocorticoids). After adjustment for relevant covariates, use of glucocorticoids was associated with a lower risk of in-hospital mortality (adjusted HR 0.44; 95% CI 0.26–0.72; p = 0.001). A significant interaction was observed between the protective effect of glucocorticoids on mortality and PaO2/FiO2 ratio on admission (p = 0.042), oxygen saturation on admission (p = 0.017), and peak CRP (0.023). Such protective effects of glucocorticoids were mainly observed in patients with lower PaO2/FiO2 ratio (<300), lower oxygen saturation ([removed]100 mg/L). Conclusions: The protective effects of glucocorticoids on mortality in COVID-19 were more evident among patients with worse respiratory parameters and higher systemic inflammation.
Published: 2021

14. The prognostic value of serial troponin measurements in patients admitted for COVID-19

Author: Nuzzi, V, Merlo, M, Specchia, C, Lombardi, C, Carubelli, V, Iorio, A, Inciardi, R, Bellasi, A, Canale, C, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Giovinazzo, S, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Oriecuia, C, Peveri, G, Pozzi, A, Provenzale, G, Sarullo, F, Tomasoni, D, Ameri, P, Gnecchi, M, Leonardi, S, Agostoni, P, Carugo, S, Danzi, G, Guazzi, M, La Rovere, M, Mortara, A, Piepoli, M, Porto, I, Volterrani, M, Senni, M, Metra, M, Sinagra, G, Nuzzi V, Merlo M, Specchia C, Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Oriecuia C, Peveri G, Pozzi A, Provenzale G, Sarullo F, Tomasoni D, Ameri P, Gnecchi M, Leonardi S, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Volterrani M, Senni M, Metra M, Sinagra G, Nuzzi, V, Merlo, M, Specchia, C, Lombardi, C, Carubelli, V, Iorio, A, Inciardi, R, Bellasi, A, Canale, C, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Giovinazzo, S, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Oriecuia, C, Peveri, G, Pozzi, A, Provenzale, G, Sarullo, F, Tomasoni, D, Ameri, P, Gnecchi, M, Leonardi, S, Agostoni, P, Carugo, S, Danzi, G, Guazzi, M, La Rovere, M, Mortara, A, Piepoli, M, Porto, I, Volterrani, M, Senni, M, Metra, M, Sinagra, G, Nuzzi V, Merlo M, Specchia C, Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Oriecuia C, Peveri G, Pozzi A, Provenzale G, Sarullo F, Tomasoni D, Ameri P, Gnecchi M, Leonardi S, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Volterrani M, Senni M, Metra M, and Sinagra G
Abstract: Aims: Myocardial injury (MI) in coronavirus disease-19 (COVID-19) is quite prevalent at admission and affects prognosis. Little is known about troponin trajectories and their prognostic role. We aimed to describe the early in-hospital evolution of MI and its prognostic impact. Methods and results: We performed an analysis from an Italian multicentre study enrolling COVID-19 patients, hospitalized from 1 March to 9 April 2020. MI was defined as increased troponin level. The first troponin was tested within 24 h from admission, the second one between 24 and 48 h. Elevated troponin was defined as values above the 99th percentile of normal values. Patients were divided in four groups: normal, normal then elevated, elevated then normal, and elevated. The outcome was in-hospital death. The study population included 197 patients; 41% had normal troponin at both evaluations, 44% had elevated troponin at both assessments, 8% had normal then elevated troponin, and 7% had elevated then normal troponin. During hospitalization, 49 (25%) patients died. Patients with incident MI, with persistent MI, and with MI only at admission had a higher risk of death compared with those with normal troponin at both evaluations (P < 0.001). At multivariable analysis, patients with normal troponin at admission and MI injury on Day 2 had the highest mortality risk (hazard ratio 3.78, 95% confidence interval 1.10–13.09, P = 0.035). Conclusions: In patients admitted for COVID-19, re-test MI on Day 2 provides a prognostic value. A non-negligible proportion of patients with incident MI on Day 2 is identified at high risk of death only by the second measurement.
Published: 2021

15. Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study

Author: Ameri, P, Inciardi, R, Di Pasquale, M, Agostoni, P, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Danzi, G, Dalla Vecchia, L, Giovinazzo, S, Gnecchi, M, Guazzi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Provenzale, G, Sarullo, F, Sinagra, G, Tedino, C, Tomasoni, D, Volterrani, M, Zaccone, G, Lombardi, C, Senni, M, Metra, M, Ameri P, Inciardi RM, Di Pasquale M, Agostoni P, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Danzi G, Dalla Vecchia L, Giovinazzo S, Gnecchi M, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Provenzale G, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Lombardi CM, Senni M, Metra M, Ameri, P, Inciardi, R, Di Pasquale, M, Agostoni, P, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Danzi, G, Dalla Vecchia, L, Giovinazzo, S, Gnecchi, M, Guazzi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Provenzale, G, Sarullo, F, Sinagra, G, Tedino, C, Tomasoni, D, Volterrani, M, Zaccone, G, Lombardi, C, Senni, M, Metra, M, Ameri P, Inciardi RM, Di Pasquale M, Agostoni P, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Danzi G, Dalla Vecchia L, Giovinazzo S, Gnecchi M, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Provenzale G, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Lombardi CM, Senni M, and Metra M
Abstract: Background: Pulmonary embolism (PE) has been described in coronavirus disease 2019 (COVID-19) critically ill patients, but the evidence from more heterogeneous cohorts is limited. Methods: Data were retrospectively obtained from consecutive COVID-19 patients admitted to 13 Cardiology Units in Italy, from March 1st to April 9th, 2020, and followed until in-hospital death, discharge, or April 23rd, 2020. The association of baseline variables with computed tomography-confirmed PE was investigated by Cox hazards regression analysis. The relationship between d-dimer levels and PE incidence was evaluated using restricted cubic splines models. Results: The study included 689 patients (67.3 ± 13.2 year-old, 69.4% males), of whom 43.6% were non-invasively ventilated and 15.8% invasively. 52 (7.5%) had PE over 15 (9–24) days of follow-up. Compared with those without PE, these subjects had younger age, higher BMI, less often heart failure and chronic kidney disease, more severe cardio-pulmonary involvement, and higher admission d-dimer [4344 (1099–15,118) vs. 818.5 (417–1460) ng/mL, p < 0.001]. They also received more frequently darunavir/ritonavir, tocilizumab and ventilation support. Furthermore, they faced more bleeding episodes requiring transfusion (15.6% vs. 5.1%, p < 0.001) and non-significantly higher in-hospital mortality (34.6% vs. 22.9%, p = 0.06). In multivariate regression, only d-dimer was associated with PE (HR 1.72, 95% CI 1.13–2.62; p = 0.01). The relation between d-dimer concentrations and PE incidence was linear, without inflection point. Only two subjects had a baseline d-dimer < 500 ng/mL. Conclusions: PE occurs in a sizable proportion of hospitalized COVID-19 patients. The implications of bleeding events and the role of d-dimer in this population need to be clarified. Graphic abstract: [Figure not available: see fulltext.].
Published: 2021

16. Winter Colour Retention and Spring Green-Up of Zoysiagrass Genotypes in Southern Europe

Author: Pompeiano, A., Grossi, N., Guglielminetti, L., and Volterrani, M.
Published: 2014

17. Monitoring Turfgrass Species and Cultivars by Spectral Reflectance

Author: Caturegli, L., Lulli, F., Foschi, L., Guglielminetti, L., Bonari, E., and Volterrani, M.
Published: 2014

18. Bermudagrass adaptation in the Mediterranean climate: phenotypic traits of 44 accessions

Author: Magni, S., Gaetani, M., Grossi, N., Caturegli, L., La Bella, S., Leto, C., Virga, G., Tuttolomondo, T., Lulli, F., and Volterrani, M.
Published: 2014

19. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Author: Zeppenfeld, K., Tfelt-Hansen, J., Riva, M. de, Winkel, B.G., Behr, E.R., Blom, N.A., Charron, P., Corrado, D., Dagres, N., Chillou, C. de, Eckardt, L., Friede, T., Haugaa, K.H., Hocini, M., Lambiase, P.D., Marijon, E., Merino, J.L., Peichl, P., Priori, S.G., Reichlin, T., Schulz-Menger, J., Sticherling, C., Tzeis, S., Verstrael, A., Volterrani, M., Cikes, M., Kirchhof, P., Abdelhamid, M., Aboyans, V., Arbelo, E., Arribas, F., Asteggiano, R., Basso, C., Bauer, A., Bertaglia, E., Biering-Sorensen, T., Blomstrom-Lundqvist, C., Borger, M.A., Celutkiene, J., Cosyns, B., Falk, V., Fauchier, L., Gorenek, B., Halvorsen, S., Hatala, R., Heidbuchel, H., Kaab, S., Konradi, A., Koskinas, K.C., Kotecha, D., Landmesser, U., Lewis, B.S., Linhart, A., Lochen, M.L., Lund, L.H., Metzner, A., Mindham, R., Nielsen, J.C., Norekval, T.M., Patten, M., Prescott, E., Rakisheva, A., Remme, C.A., Roca-Luque, I., Sarkozy, A., Scherr, D., Sitges, M., Touyz, R.M., Mieghem, N. van, Velagic, V., Viskin, S., Volders, P.G.A., Task Force Members, and ESC Scientific Document Group
Subjects: Genetic testing, Cardiac magnetic resonance, Sudden death, Ventricular tachycardia, Primary electrical disease, Guidelines, Recommendations, Chronic coronary artery disease, Risk calculator, Sudden cardiac death, Implantable cardioverter defibrillator, Ventricular arrhythmia, Catheter ablation, Anti-arrhythmic drugs, Ventricular fibrillation, Cardiomyopathies, Risk stratification, Premature ventricular complex
Published: 2022

20. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author: González, A, Richards, AM, de Boer, RA, Thum, T, Arfsten, H, Hülsmann, M, Falcao-Pires, I, Díez, J, Foo, RS, Chan, MYY, Aimo, A, Anene-Nzelu, GC, Abdelhamid, M, Adamopoulos, S, Anker, SD, Belenkov, Y, Gal, TB, Cohen-Solal, A, Böhm, M, Chioncel, O, Delgado, V, Emdin, M, Jankowska, EA, Gustafsson, F, Hill, L, Jaarsma, T, Januzzi, JL, Jhund, PS, Lopatin, Y, Lund, LH, Metra, M, Milicic, D, Moura, B, Mueller, C, Mullens, W, Núñez, J, Piepoli, MF, Rakisheva, A, Ristic, A, Rossignol, P, Savarese, G, Tocchetti, CG, Van Linthout, S, Volterrani, M, Seferovic, P, Rosano, G, Coats, AJ, and Bayes-Genis, A
Abstract: Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling.
Published: 2022

21. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study

Author: Pagnesi, M., Inciardi, R. M., Lombardi, C. M., Agostoni, P., Ameri, P., Barbieri, L., Bellasi, A., Camporotondo, R., Canale, C., Carubelli, V., Carugo, S., Catagnano, F., Dalla Vecchia, L. A., Danzi, G. B., Di Pasquale, M., Gaudenzi, M., Giovinazzo, S., Gnecchi, M., Guazzi, M., Iorio, A., La Rovere, M. T., Leonardi, S., Maccagni, G., Mapelli, M., Margonato, D., Merlo, M., Monzo, L., Mortara, A., Nuzzi, V., Piepoli, M., Porto, I., Pozzi, A., Sarullo, F., Sinagra, G., Tedino, C., Tomasoni, D., Volterrani, M., Zaccone, G., Senni, M., Metra, M., Pagnesi, M, Inciardi, R, Lombardi, C, Agostoni, P, Ameri, P, Barbieri, L, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Dalla Vecchia, L, Danzi, G, Di Pasquale, M, Gaudenzi, M, Giovinazzo, S, Gnecchi, M, Guazzi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Sarullo, F, Sinagra, G, Tedino, C, Tomasoni, D, Volterrani, M, Zaccone, G, Senni, M, Metra, M, Pagnesi, M., Inciardi, R. M., Lombardi, C. M., Agostoni, P., Ameri, P., Barbieri, L., Bellasi, A., Camporotondo, R., Canale, C., Carubelli, V., Carugo, S., Catagnano, F., Dalla Vecchia, L. A., Danzi, G. B., Di Pasquale, M., Gaudenzi, M., Giovinazzo, S., Gnecchi, M., Guazzi, M., Iorio, A., La Rovere, M. T., Leonardi, S., Maccagni, G., Mapelli, M., Margonato, D., Merlo, M., Monzo, L., Mortara, A., Nuzzi, V., Piepoli, M., Porto, I., Pozzi, A., Sarullo, F., Sinagra, G., Tedino, C., Tomasoni, D., Volterrani, M., Zaccone, G., Senni, M., and Metra, M.
Subjects: SARS-CoV-2, Short Communication, COVID-19, corticosteroid, glucocorticoid, steroid, Glucocorticoid, Italy, Corticosteroid, Steroid, Hospital Mortality, Humans, Retrospective Studies, Glucocorticoids
Abstract: Background: Glucocorticoid therapy has emerged as an effective therapeutic option in hospitalized patients with coronavirus disease 2019 (COVID-19). This study aimed to focus on the impact of relevant clinical and laboratory factors on the protective effect of glucocorticoids on mortality. Methods: A sub-analysis was performed of the multicenter Cardio-COVID-Italy registry, enrolling consecutive patients with COVID-19 admitted to 13 Italian cardiology units between 01 March 2020 and 09 April 2020. The primary endpoint was in-hospital mortality. Results: A total of 706 COVID-19 patients were included (349 treated with glucocorticoids, 357 not treated with glucocorticoids). After adjustment for relevant covariates, use of glucocorticoids was associated with a lower risk of in-hospital mortality (adjusted HR 0.44; 95% CI 0.26–0.72; p = 0.001). A significant interaction was observed between the protective effect of glucocorticoids on mortality and PaO2/FiO2 ratio on admission (p = 0.042), oxygen saturation on admission (p = 0.017), and peak CRP (0.023). Such protective effects of glucocorticoids were mainly observed in patients with lower PaO2/FiO2 ratio (100 mg/L). Conclusions: The protective effects of glucocorticoids on mortality in COVID-19 were more evident among patients with worse respiratory parameters and higher systemic inflammation.
Published: 2021

22. Clinical utility of ivabradine in cardiovascular disease management: current status

Author: Rosano GMC, Vitale C, Spoletini I, and Volterrani M
Subjects: Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: Giuseppe MC Rosano,1,2 Cristiana Vitale,1,2 Ilaria Spoletini,1 Maurizio Volterrani11Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy; 2Cardiovascular and Cell Sciences Research Institute, St George's University of London, London, UK Abstract: Ivabradine is a selective antagonist of the funny channels with anti-anginal and anti-ischemic properties, approved for the treatment of coronary artery disease (CAD) and heart failure (HF). It provides pure heart rate reduction, reducing the diastolic depolarization slope, without altering hemodynamic parameters. This review summarizes the current knowledge on the efficacy of ivabradine in patients with cardiovascular diseases, with a particular focus on its role in the clinical management of patients with CAD and HF. There is consistent evidence that ivabradine is effective in reducing angina pectoris symptoms and myocardial ischemia. At approved doses ivabradine is safe, improves exercise tolerance, and reduces heart rate. Available data from clinical trials support its use in the management of patients with stable CAD and chronic HF. Recent studies have cast doubt on the safety of non-approved high doses of ivabradine for the treatment of patients with CAD and without clinical HF, but have shown no concerns on the doses approved for clinical use. Keywords: ivabradine, coronary artery disease, heart failure, angina pectoris, exercise performance
Published: 2014

23. Association of Troponin Levels with Mortality in Italian Patients Hospitalized with Coronavirus Disease 2019: Results of a Multicenter Study

Author: Lombardi, C, Carubelli, V, Iorio, A, Inciardi, R, Bellasi, A, Canale, C, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Giovinazzo, S, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Nuzzi, V, Oriecuia, C, Peveri, G, Pozzi, A, Provenzale, G, Sarullo, F, Tomasoni, D, Ameri, P, Gnecchi, M, Leonardi, S, Merlo, M, Agostoni, P, Carugo, S, Danzi, G, Guazzi, M, La Rovere, M, Mortara, A, Piepoli, M, Porto, I, Sinagra, G, Volterrani, M, Specchia, C, Metra, M, Senni, M, Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Oriecuia C, Peveri G, Pozzi A, Provenzale G, Sarullo F, Tomasoni D, Ameri P, Gnecchi M, Leonardi S, Merlo M, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, Specchia C, Metra M, Senni M, Lombardi, C, Carubelli, V, Iorio, A, Inciardi, R, Bellasi, A, Canale, C, Camporotondo, R, Catagnano, F, Dalla Vecchia, L, Giovinazzo, S, Maccagni, G, Mapelli, M, Margonato, D, Monzo, L, Nuzzi, V, Oriecuia, C, Peveri, G, Pozzi, A, Provenzale, G, Sarullo, F, Tomasoni, D, Ameri, P, Gnecchi, M, Leonardi, S, Merlo, M, Agostoni, P, Carugo, S, Danzi, G, Guazzi, M, La Rovere, M, Mortara, A, Piepoli, M, Porto, I, Sinagra, G, Volterrani, M, Specchia, C, Metra, M, Senni, M, Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Oriecuia C, Peveri G, Pozzi A, Provenzale G, Sarullo F, Tomasoni D, Ameri P, Gnecchi M, Leonardi S, Merlo M, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, Specchia C, Metra M, and Senni M
Abstract: Importance: Myocardial injury, detected by elevated plasma troponin levels, has been associated with mortality in patients hospitalized with coronavirus disease 2019 (COVID-19). However, the initial data were reported from single-center or 2-center studies in Chinese populations. Compared with these patients, European and US patients are older, with more comorbidities and higher mortality rates. Objective: To evaluate the prevalence and prognostic value of myocardial injury, detected by elevated plasma troponin levels, in a large population of White Italian patients with COVID-19. Design, Setting, and Participants: This is a multicenter, cross-sectional study enrolling consecutive patients with laboratory-confirmed COVID-19 who were hospitalized in 13 Italian cardiology units from March 1 to April 9, 2020. Patients admitted for acute coronary syndrome were excluded. Elevated troponin levels were defined as values greater than the 99th percentile of normal values. Main Outcomes and Measures: Clinical characteristics and outcomes stratified as elevated or normal cardiac troponin levels at admission, defined as troponin T or troponin I at a level greater than the 99th percentile of normal values. Results: A total of 614 patients with COVID-19 were included in this study (mean age [SD], 67 [13] years; 70.8% male), of whom 148 patients (24.1%) died during the hospitalization. Elevated troponin levels were found in 278 patients (45.3%). These patients were older (mean [SD] age, 64.0 [13.6] years vs 71.3 [12.0] years; P <.001) and had higher prevalence of hypertension (168 patients [50.5%] vs 182 patients [65.9%]; P <.001), heart failure (24 [7.2%]; 63 [22.8%]; P <.001), coronary artery disease (50 [15.0%] vs 87 [31.5%]; P <.001), and atrial fibrillation (33 [9.9%] vs 67 [24.3%]; P <.001). Elevated troponin levels were associated with an increased in-hospital mortality (37% vs 13%; HR, 1.71 [95% CI, 1.13-2.59]; P =.01 via multivariable Cox regression analysi
Published: 2020

24. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study

Author: Tomasoni, D, Inciardi, R, Lombardi, C, Tedino, C, Agostoni, P, Ameri, P, Barbieri, L, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Dalla Vecchia, L, Danzi, G, Di Pasquale, M, Gaudenzi, M, Giovinazzo, S, Gnecchi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Sarullo, F, Sinagra, G, Volterrani, M, Zaccone, G, Guazzi, M, Senni, M, Metra, M, Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, Gnecchi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Volterrani M, Zaccone G, Guazzi M, Senni M, Metra M, Tomasoni, D, Inciardi, R, Lombardi, C, Tedino, C, Agostoni, P, Ameri, P, Barbieri, L, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Dalla Vecchia, L, Danzi, G, Di Pasquale, M, Gaudenzi, M, Giovinazzo, S, Gnecchi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Sarullo, F, Sinagra, G, Volterrani, M, Zaccone, G, Guazzi, M, Senni, M, Metra, M, Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, Gnecchi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Volterrani M, Zaccone G, Guazzi M, Senni M, and Metra M
Abstract: Aims: To assess the prognostic value of a history of heart failure (HF) in patients with coronavirus disease 2019 (COVID-19). Methods and results: We enrolled 692 consecutive patients admitted for COVID-19 in 13 Italian cardiology centres between 1 March and 9 April 2020. Mean age was 67.4 ± 13.2 years, 69.5% of patients were males, 90 (13.0%) had a history of HF, median hospitalization length was 14 days (interquartile range 9–24). In-hospital death occurred in 37 of 90 patients (41.1%) with HF history vs. 126 of those with no HF history (20.9%). The increased risk of death associated with HF history remained significant after adjustment for clinical variables related to COVID-19 and HF severity, including comorbidities, oxygen saturation, lymphocyte count and plasma troponin [adjusted hazard ratio (HR) for death: 2.25; 95% confidence interval (CI) 1.26–4.02; P = 0.006 at multivariable Cox regression model including 404 patients]. Patients with a history of HF also had more in-hospital complications including. acute HF (33.3% vs. 5.1%, P < 0.001), acute renal failure (28.1% vs. 12.9%, P < 0.001), multiorgan failure (15.9% vs. 5.8%, P = 0.004) and sepsis (18.4% vs. 8.9%, P = 0.006). Other independent predictors of outcome were age, sex, oxygen saturation and oxygen partial pressure at arterial gas analysis/fraction of inspired oxygen ratio (PaO2/FiO2). In-hospital treatment with corticosteroids and heparin had beneficial effects (adjusted HR for death: 0.46; 95% CI 0.29–0.74; P = 0.001; n = 404 for corticosteroids, and adjusted HR 0.41; 95% CI 0.25–0.67; P < 0.001; n = 364 for heparin). Conclusions: Hospitalized patients with COVID-19 and a history of HF have an extremely poor outcome with higher mortality and in-hospital complications. HF history is an independent predictor of increased in-hospital mortality.
Published: 2020

25. Physiological responses of c₄ grasses to prolonged heat stress

Author: Pompeiano, A., Volterrani, M., and Guglielminetti, L.
Published: 2013

26. Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry

Author: Salzano, A, D'Assante, R, Iacoviello, M, Triggiani, V, Rengo, G, Cacciatore, F, Maiello, C, Limongelli, G, Masarone, D, Sciacqua, A, Perrone Filardi, P, Mancini, A, Volterrani, M, Vriz, O, Castello, R, Passantino, A, Campo, M, Modesti, Pa, De Giorgi, A, Arcopinto, M, Gargiulo, P, Perticone, M, Colao, A, Milano, S, Garavaglia, A, Napoli, R, Suzuki, T, Bossone, E, Marra, Am, Cittadini, A, Saccà, L, Monti, Mg, Matarazzo, M, Stagnaro, Fm, Piccioli, L, Lombardi, A, Panicara, V, Flora, M, Golia, L, Faga, V, Ruocco, A, Della Polla, D, Franco, R, Schiavo, A, Gigante, A, Spina, E, Sicuranza, M, Monaco, F, Apicella, M, Miele, C, Campanino, Ag, Mazza, L, Abete, R, Farro, A, Luciano, F, Polizzi, R, Ferrillo, G, De Luca, M, Crisci, G, Giardino, F, Barbato, M, Ranieri, B, Ferrara, F, Russo, V, Malinconico, M, Citro, R, Guastalamacchia, E, Leone, M, Giagulli, Va, Amarelli, C, Mattucci, I, Calabrò, P, Calabrò, R, D'Andrea, A, Maddaloni, V, Pacileo, G, Scarafile, R, Belfiore, A, Cimellaro, A, Casaretti, L, Paolillo, S, Favuzzi, Amr, Di Segni, C, Bruno, C, Vergani, E, Massaro, R, Grimaldi, F, Frigo, A, Sorrentino, Mr, Malandrino, D, Manfredini, R, Fabbian, F, Puzzo, A, Ragusa, L, Caliendo, L, Carbone, L, Frigiola, A, Generali, T, Giacomazzi, F, De Vincentiis, C, Ballotta, A, Garofalo, P, Malizia, G, Misiano, G, Israr, Mz, Bernieh, D, Cassambai, S, Yazaki, Y, Heaney, Lm, Eagle, Ka, Ventura, Ho, Bruzzese, D, Salzano, Andrea, D'Assante, Roberta, Iacoviello, Massimo, Triggiani, Vincenzo, Rengo, Giuseppe, Cacciatore, Francesco, Maiello, Ciro, Limongelli, Giuseppe, Masarone, Daniele, Sciacqua, Angela, Filardi, Pasquale Perrone, Mancini, Antonio, Volterrani, Maurizio, Vriz, Olga, Castello, Roberto, Passantino, Andrea, Campo, Michela, Modesti, Pietro A, De Giorgi, Alfredo, Arcopinto, Michele, Gargiulo, Paola, Perticone, Maria, Colao, Annamaria, Milano, Salvatore, Garavaglia, Agnese, Napoli, Raffaele, Suzuki, Toru, Bossone, Eduardo, Marra, Alberto M, Cittadini, Antonio, and Misiano, Gabriella
Subjects: Registrie, Heart Failure, Endocrinology, Diabetes and Metabolism, Ventricular Dysfunction, Right, Diabetes, Insulins, Socio-culturale, Stroke Volume, Insulin resistance, Diabete, Cardiopulmonary exercise test, Chronic heart failure, Diabetes, Insulin resistance, Right ventricle, TOSCA Registry, Chronic heart failure, Diabetes Mellitus, Type 2, TOSCA Registry, Exercise Test, Ventricular Function, Right, Humans, Insulin, Right ventricle, Registries, Cardiology and Cardiovascular Medicine, Cardiopulmonary exercise test, TOSCA, Human, LS4_7
Abstract: Background Findings from the T.O.S.CA. Registry recently reported that patients with concomitant chronic heart failure (CHF) and impairment of insulin axis (either insulin resistance—IR or diabetes mellitus—T2D) display increased morbidity and mortality. However, little information is available on the relative impact of IR and T2D on cardiac structure and function, cardiopulmonary performance, and their longitudinal changes in CHF. Methods Patients enrolled in the T.O.S.CA. Registry performed echocardiography and cardiopulmonary exercise test at baseline and at a patient-average follow-up of 36 months. Patients were divided into three groups based on the degree of insulin impairment: euglycemic without IR (EU), euglycemic with IR (IR), and T2D. Results Compared with EU and IR, T2D was associated with increased filling pressures (E/e′ratio: 15.9 ± 8.9, 12.0 ± 6.5, and 14.5 ± 8.1 respectively, p 2) in TD2 vs EU and IR patients was recorded (respectively, 15.8 ± 3.8 ml/Kg/min, 18.4 ± 4.3 ml/Kg/min and 16.5 ± 4.3 ml/Kg/min, p 2 in the T2D group (+ 13% increase in RV dimension, − 21% decline in TAPSE/PAPS ratio and − 20% decrease in peak VO2). Conclusion The higher risk of death and CV hospitalizations exhibited by HF-T2D patients in the T.O.S.CA. Registry is associated with progressive RV ventricular dysfunction and exercise impairment when compared to euglycemic CHF patients, supporting the pivotal importance of hyperglycaemia and right chambers in HF prognosis. Trial registration ClinicalTrials.gov identifier: NCT023358017
Published: 2022

27. Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author: Aimo, A, Vergaro, G, Gonzalez, A, Barison, A, Lupon, J, Delgado, V, Richards, AM, de Boer, RA, Thum, T, Arfsten, H, Hulsmann, M, Falcao-Pires, I, Diez, J, Foo, RSY, Chan, MYY, Anene-Nzelu, CG, Abdelhamid, M, Adamopoulos, S, Anker, SD, Belenkov, Y, Gal, TB, Cohen-Solal, A, Bohm, M, Chioncel, O, Jankowska, EA, Gustafsson, F, Hill, L, Jaarsma, T, Januzzi, JL, Jhund, P, Lopatin, Y, Lund, LH, Metra, M, Milicic, D, Moura, B, Mueller, C, Mullens, W, Nunez, J, Piepoli, MF, Rakisheva, A, Ristic, AD, Rossignol, P, Savarese, G, Tocchetti, CG, van Linthout, S, Volterrani, M, Seferovic, P, Rosano, G, Coats, AJS, Emdin, M, and Bayes-Genis, A
Subjects: Ejection fraction, Predictors, Therapies, Remodelling, Heart failure, Biomarkers, Imaging
Abstract: In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.
Published: 2022

28. Poster session 1: Wednesday 3 December 2014, 09: 00–16: 00Location: Poster area

Author: Caminiti, G, Dʼantoni, V, Dʼantoni, V, Cardaci, V, Cardaci, V, Conti, V, Conti, V, Volterrani, M, and Volterrani, M
Published: 2014

29. Effects of Application of Municipal Solid Waste Compost on Horticultural Species Yield

Author: Volterrani, M., Pardini, G., Gaetani, M., Grossi, N., Miele, S., de Bertoldi, Marco, editor, Sequi, Paolo, editor, Lemmes, Bert, editor, and Papi, Tiziano, editor
Published: 1996
Full Text: View/download PDF

30. Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry

Author: Cittadini A., Salzano A., Iacoviello M., Triggiani V., Rengo G., Cacciatore F., Maiello C., Limongelli G., Masarone D., Perticone F., Cimellaro A., Filardi P. P., Paolillo S., Mancini A., Volterrani M., Vriz O., Castello R., Passantino A., Campo M., Modesti P. A., de Giorgi A., Monte I. P., Puzzo A., Ballotta A., D'Assante R., Arcopinto M., Gargiulo P., Sciacqua A., Bruzzese D., Colao A., Napoli R., Suzuki T., Eagle K. A., Ventura H. O., Marra A. M., Bossone E., Sacca L., Monti M. G., Matarazzo M., Stagnaro F. M., Piccioli L., Lombardi A., Panicara V., Flora M., Golia L., Faga V., Ruocco A., della Polla D., Franco R., Schiavo A., Gigante A., Spina E., Sicuranza M., Monaco F., Apicella M., Miele C., Campanino A. G., Mazza L., Abete R., Farro A., Luciano F., Polizzi R., Ferrillo G., de Luca M., Crisci G., Giardino F., Barbato M., Ranieri B., Ferrara F., Russo V., Malinconico M., Citro R., Guastalamacchia E., Leone M., Giagulli V. A., Amarelli C., Mattucci I., Calabro P., Calabro R., D'Andrea A., Maddaloni V., Pacileo G., Scarafile R., Belfiore A., Casaretti L., Favuzzi A. M. R., Di Segni C., Bruno C., Vergani E., Massaro R., Grimaldi F., Frigo A., Campo M. R., Sorrentino M. R., Malandrino D., Manfredini R., Fabbian F., Ragusa L., Caliendo L., Carbone L., Frigiola A., Generali T., Giacomazzi F., de Vincentiis C., Garofalo P., Malizia G., Milano S., Misiano G., Israr M. Z., Bernieh D., Cassambai S., Yazaki Y., Heaney L. M., Cittadini, Antonio, Salzano, Andrea, Iacoviello, Massimo, Triggiani, Vincenzo, Rengo, Giuseppe, Cacciatore, Francesco, Maiello, Ciro, Limongelli, Giuseppe, Masarone, Daniele, Perticone, Francesco, Cimellaro, Antonio, Perrone Filardi, Pasquale, Paolillo, Stefania, Mancini, Antonio, Volterrani, Maurizio, Vriz, Olga, Castello, Roberto, Passantino, Andrea, Campo, Michela, Modesti, Pietro A, De Giorgi, Alfredo, Monte, Ines P, Puzzo, Alfonso, Ballotta, Andrea, D'Assante, Roberta, Arcopinto, Michele, Gargiulo, Paola, Sciacqua, Angela, Bruzzese, Dario, Colao, Annamaria, Napoli, Raffaele, Suzuki, Toru, Eagle, Kim A, Ventura, Hector O, Marra, Alberto M, Bossone, Eduardo, Cittadini, A., Salzano, A., Iacoviello, M., Triggiani, V., Rengo, G., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Cimellaro, A., Filardi, P. P., Paolillo, S., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., de Giorgi, A., Monte, I. P., Puzzo, A., Ballotta, A., D'Assante, R., Arcopinto, M., Gargiulo, P., Sciacqua, A., Bruzzese, D., Colao, A., Napoli, R., Suzuki, T., Eagle, K. A., Ventura, H. O., Marra, A. M., Bossone, E., Sacca, L., Monti, M. G., Matarazzo, M., Stagnaro, F. M., Piccioli, L., Lombardi, A., Panicara, V., Flora, M., Golia, L., Faga, V., Ruocco, A., della Polla, D., Franco, R., Schiavo, A., Gigante, A., Spina, E., Sicuranza, M., Monaco, F., Apicella, M., Miele, C., Campanino, A. G., Mazza, L., Abete, R., Farro, A., Luciano, F., Polizzi, R., Ferrillo, G., de Luca, M., Crisci, G., Giardino, F., Barbato, M., Ranieri, B., Ferrara, F., Russo, V., Malinconico, M., Citro, R., Guastalamacchia, E., Leone, M., Giagulli, V. A., Amarelli, C., Mattucci, I., Calabro, P., Calabro, R., D'Andrea, A., Maddaloni, V., Pacileo, G., Scarafile, R., Belfiore, A., Casaretti, L., Favuzzi, A. M. R., Di Segni, C., Bruno, C., Vergani, E., Massaro, R., Grimaldi, F., Frigo, A., Campo, M. R., Sorrentino, M. R., Malandrino, D., Manfredini, R., Fabbian, F., Ragusa, L., Caliendo, L., Carbone, L., Frigiola, A., Generali, T., Giacomazzi, F., de Vincentiis, C., Garofalo, P., Malizia, G., Milano, S., Misiano, G., Israr, M. Z., Bernieh, D., Cassambai, S., Yazaki, Y., and Heaney, L. M.
Subjects: medicine.medical_specialty, Multiple hormonal and metabolic deficiency syndrome, Epidemiology, Prognosi, Anabolic deficiency, Socio-culturale, Heart failure, 030204 cardiovascular system & hematology, Ventricular Function, Left, 03 medical and health sciences, 0302 clinical medicine, Insulin resistance, Diabetes mellitus, Internal medicine, Multiple hormonal, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Prospective Studies, Registries, TOSCA, LS4_7, Ejection fraction, business.industry, Hazard ratio, Metabolic deficiency syndrome, Heart failure • Anabolic deficiency • Multiple hormonal and metabolic deficiency syndrome • Hormones • Prognosis • TOSCA, Stroke Volume, medicine.disease, Prognosis, Hormone, Confidence interval, Heart failure, Anabolic deficiency, Multiple hormonal and metabolic deficiency syndrome, Hormones, Prognosis, TOSCA, Hormones, Hospitalization, Observational study, Cardiology and Cardiovascular Medicine, business
Abstract: Aims Recent evidence supports the occurrence of multiple hormonal and metabolic deficiency syndrome (MHDS) in chronic heart failure (CHF). However, no large observational study has unequivocally demonstrated its impact on CHF progression and outcome. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Treatment in Heart Failure) Registry has been specifically designed to test the hypothesis that MHDS affects morbidity and mortality in CHF patients. Methods and Results The T.O.S.CA. Registry is a prospective, multicentre, observational study involving 19 Italian centres. Thyroid hormones, insulin-like growth factor-1, total testosterone, dehydropianoandrosterone sulfate, insulin resistance, and the presence of diabetes were evaluated. A MHDS was defined as the presence of ≥2 hormone deficiencies (HDs). Primary endpoint was a composite of all-cause mortality and cardiovascular hospitalizations. Four hundred and eighty heart failure patients with ejection fraction ≤45% were enrolled. MHDS or diabetes was diagnosed in 372 patients (77.5%). A total of 271 events (97 deaths and 174 cardiovascular hospitalizations) were recorded, 41% in NO-MHDS and 62% in MHDS (P Conclusion MHDS is common in CHF and independently associated with increased all-cause mortality and cardiovascular hospitalization, representing a promising therapeutic target. Trial registration ClinicalTrials.gov identifier: NCT023358017
Published: 2021

31. Hemodynamic responses associated with post-exercise hypotension in hypertensive patients with ischemic heart disease: concurrent circuit exercise versus high intensity interval exercise

Author: Caminiti, G, primary, Iellamo, F, additional, D"antoni, V, additional, Catena, M, additional, Perrone, M, additional, Morsella, V, additional, and Volterrani, M, additional
Published: 2022
Full Text: View/download PDF

32. Comparative long term effects of Nebivolol and Carvedilol in hypertensive heart failure patients: P946

Author: Marazzi, G, Caminiti, G, Campolongo, G, Sposato, B, Massaro, R, Vitale, C, Rosano, G M C Giuseppe M C, and Volterrani, M
Published: 2016

33. Plasma testosterone levels in men with ischemic left ventricular dysfunction: P865

Author: Rosano, G M C Giuseppe M C, Aversa, A, Marazzi, G, Vitale, C, Massaro, R, and Volterrani, M
Published: 2016

34. Comment on: Relation of blood pressure variability to left ventricular function and arterial stiffness in hypertensive patients

Author: Caminiti, G, primary, Ferdinando, I, additional, Rosalba, M, additional, and Volterrani, M, additional
Published: 2021
Full Text: View/download PDF

35. Correlation Between Systolic Blood Pressure Variability and Global Longitudinal Strain in Patients with Parkinson's Disease and Dysautonomia

Author: D’Antoni, Morsella, L Vacca, Stocchi F, M Torti, S Selli, Paola Grassini, Volterrani M, and Caminiti G
Subjects: medicine.medical_specialty, Ejection fraction, Ambulatory blood pressure, Parkinson's disease, business.industry, Dysautonomia, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, Orthostatic vital signs, 0302 clinical medicine, Blood pressure, Internal medicine, Cardiology, medicine, Mass index, medicine.symptom, Cardiology and Cardiovascular Medicine, business, 030217 neurology & neurosurgery, Subclinical infection
Abstract: Background: Patients with Parkinsons disease (PD) and dysautonomia often present elevated blood pressure (BP) variability. However if the elevate BP variability is correlated with subclinical echocardiography abnormalities have been poorly investigated yet. Our aim was to evaluate the correlation between indices of left ventricular function and 24/h BP variability in patients with PD. Methods: We studied 21 patients with diagnosed PD and autonomic dysfunction and 20 hypertensive age-matched subjects. All patients underwent 24/h ambulatory blood pressure monitoring (ABPM) and echocardiography. Left ventricular (LV) systolic function was evaluated by ejection fraction (EF), tissue Doppler s wave and global longitudinal strain (GLS). BP variability was evaluated through average real variability. Results: At ABPM, patients with PD had an higher occurrence of nocturnal hypertension, orthostatic hypotension and post-prandial hypotension compared to hypertensive subjects. GLS, tissue Doppler s velocity, LVEF, LV mass index, and E/e ratio were similar between the patients with PD and those with hypertension. In patients with PD there was a significant correlation between GLS and 24/h systolic BP variability (r= 0.44; p=0.01). a trend through significance between 24 systolic BP variability and tissue Doppler s velocity (r= -0.31; p=0.06). Conclusions: In PD patients, short-term BP variability was inversely related to GLS. GLS seems to be an early detector of LV dysfunction in patients with PD and autonomic dysfunction.
Published: 2020

36. Poster session 3: Thursday 4 December 2014, 14: 00–18: 00Location: Poster area

Author: Caminiti, G, Dʼantoni, V, Cardaci, V, Conti, V, and Volterrani, M
Published: 2014

37. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology

Author: Rosano, G.M.C. Moura, B. Metra, M. Böhm, M. Bauersachs, J. Ben Gal, T. Adamopoulos, S. Abdelhamid, M. Bistola, V. Čelutkienė, J. Chioncel, O. Farmakis, D. Ferrari, R. Filippatos, G. Hill, L. Jankowska, E.A. Jaarsma, T. Jhund, P. Lainscak, M. Lopatin, Y. Lund, L.H. Milicic, D. Mullens, W. Pinto, F. Ponikowski, P. Savarese, G. Thum, T. Volterrani, M. Anker, S.D. Seferovic, P.M. Coats, A.J.S.
Abstract: Despite guideline recommendations and available evidence, implementation of treatment in heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses that have been proven to positively impact morbidity and mortality. Among others, tolerability issues related to low blood pressure, heart rate, impaired renal function or hyperkalaemia are responsible. Chronic kidney disease plays an important role as it affects up to 50% of patients with HF. Also, dynamic changes in estimated glomerular filtration rate may occur during the course of HF, resulting in inappropriate dose reduction or even discontinuation of decongestive or neurohormonal modulating therapy in clinical practice. As patients with HF are rarely naïve to pharmacologic therapies, the challenge is to adequately prioritize or select the most appropriate up-titration schedule according to patient profile. In this consensus document, we identified nine patient profiles that may be relevant for treatment implementation in HF patients with a reduced ejection fraction. These profiles take into account heart rate (70 bpm), the presence of atrial fibrillation, symptomatic low blood pressure, estimated glomerular filtration rate (30 mL/min/1.73 m2) or hyperkalaemia. The pre-discharge patient, frequently still congestive, is also addressed. A personalized approach, adjusting guideline-directed medical therapy to patient profile, may allow to achieve a better and more comprehensive therapy for each individual patient than the more traditional, forced titration of each drug class before initiating treatment with the next. © 2021 European Society of Cardiology
Published: 2021

38. Coupling Between Atrial Function and Exercise Tolerance in a Patient with Heart Failure and Atrial Fibrillation Treated with Sacubitril-Valsartan and Combined Exercise

Author: Catena M, D’Antoni, Morsella, Ferdinando Iellamo, Volterrani M, and Caminiti G
Subjects: medicine.medical_specialty, Rehabilitation, Ejection fraction, business.industry, medicine.medical_treatment, Atrial fibrillation, General Medicine, medicine.disease, Male patient, Left atrial, Heart failure, Internal medicine, cardiovascular system, Cardiology, Medicine, cardiovascular diseases, business, Sacubitril, Valsartan
Abstract: A 50 years old male patient with heart failure with reduced ejection fraction and permanent atrial fibrillation, referred to our centre for a cardiac rehabilitation program. He had a very limited exercise tolerance and presented a very compromised atrial function at 2D spleckle tracking echocardiography. Both exercise tolerance and left atrial function improved greatly after a comprehensive intervention including sacubitrilvalsartan administration and exercise training. These benefits, partially, persisted 8 weeks after training cessation. This is the first demonstration of an improvement in left atrial function in a patient, with heart failure and atrial fibrillation, produced by a therapeutic intervention.
Published: 2021

39. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry

Author: Bossone, E., Arcopinto, M., Iacoviello, M., Triggiani, V., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Sciacqua, A., Perrone-Filardi, P., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., de Giorgi, A., Monte, I., Puzzo, A., Ballotta, A., Caliendo, L., D’Assante, R., Marra, A. M., Salzano, A., Suzuki, T., Cittadini, A., Saccà, L., Monti, M. G., Napoli, R., Matarazzo, M., Stagnaro, F. M., Schiavo, A., Valente, P., Ferrara, F., Russo, V., Malinconico, M., Citro, R., Guastalamacchia, E., Leone, M., Amarelli, C., Mattucci, I., Calabrò, P., Calabrò, R., D’Andrea, A., Maddaloni, V., Pacileo, G., Scarafile, R., Belfiore, A., Cimellaro, A., Perrone Filardi, P., Casaretti, L., Paolillo, S., Gargiulo, P., Favuzzi, A. M. R., Di Segni, C., Bruno, C., Vergani, E., Massaro, R., Grimaldi, F., Frigo, A., Sorrentino, M. R., Malandrino, D., Manfredini, R., Fabbian, F., Ragusa, L., Carbone, L., Frigiola, A., Generali, T., Giacomazzi, F., de Vincentiis, C., Garofalo, P., Malizia, G., Milano, S., Misiano, G., Heaney, L. M., Bruzzese, D., Bossone E., Arcopinto M., Iacoviello M., Triggiani V., Cacciatore F., Maiello C., Limongelli G., Masarone D., Perticone F., Sciacqua A., Perrone-Filardi P., Mancini A., Volterrani M., Vriz O., Castello R., Passantino A., Campo M., Modesti P.A., De Giorgi A., Monte I., Puzzo A., Ballotta A., Caliendo L., D'Assante R., Marra A.M., Salzano A., Suzuki T., Cittadini A., Sacca L., Monti M.G., Napoli R., Matarazzo M., Stagnaro F.M., Schiavo A., Valente P., Ferrara F., Russo V., Malinconico M., Citro R., Guastalamacchia E., Leone M., Amarelli C., Mattucci I., Calabro P., Calabro R., D'Andrea A., Maddaloni V., Pacileo G., Scarafile R., Belfiore A., Cimellaro A., Casaretti L., Paolillo S., Gargiulo P., Favuzzi A.M.R., DiSegni C., Bruno C., Vergani E., Massaro R., Grimaldi F., Frigo A., Sorrentino M.R., Malandrino D., Manfredini R., DeGiorgi A., Fabbian F., Ragusa L., Carbone L., Frigiola A., Generali T., Giacomazzi F., DeVincentiis C., Garofalo P., Malizia G., Milano S., Misiano G., Heaney L.M., Bruzzese D., Bossone, E, Arcopinto, M, Iacoviello, M, Triggiani, V, Cacciatore, F, Maiello, C, Limongelli, G, Masarone, D, Perticone, F, Sciacqua, A, Perrone-Filardi, P, Mancini, A, Volterrani, M, Vriz, O, Castello, R, Passantino, A, Campo, M, A Modesti, P, De Giorgi, A, Monte, I, Puzzo, A, Ballotta, A, Caliendo, L, D'Assante, R, M Marra, A, Salzano, A, Suzuki, T, Cittadini, A, Investigators, Tosca, Bossone, E., Arcopinto, M., Iacoviello, M., Triggiani, V., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Sciacqua, A., Perrone-Filardi, P., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., de Giorgi, A., Monte, I., Puzzo, A., Ballotta, A., Caliendo, L., D’Assante, R., Marra, A. M., Salzano, A., Suzuki, T., Cittadini, A., Saccà, L., Monti, M. G., Napoli, R., Matarazzo, M., Stagnaro, F. M., Schiavo, A., Valente, P., Ferrara, F., Russo, V., Malinconico, M., Citro, R., Guastalamacchia, E., Leone, M., Amarelli, C., Mattucci, I., Calabrò, P., Calabrò, R., D’Andrea, A., Maddaloni, V., Pacileo, G., Scarafile, R., Belfiore, A., Cimellaro, A., Perrone Filardi, P., Casaretti, L., Paolillo, S., Gargiulo, P., Favuzzi, A. M. R., Di Segni, C., Bruno, C., Vergani, E., Massaro, R., Grimaldi, F., Frigo, A., Sorrentino, M. R., Malandrino, D., Manfredini, R., Fabbian, F., Ragusa, L., Carbone, L., Frigiola, A., Generali, T., Giacomazzi, F., de Vincentiis, C., Garofalo, P., Malizia, G., Milano, S., Misiano, G., Heaney, L. M., and Bruzzese, D.
Subjects: Male, Anabolism, medicine.medical_treatment, 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Clinical endpoint, Medicine, Deficiency Disease, 030212 general & internal medicine, Prospective Studies, Registries, Prospective cohort study, Testosterone, Anabolic deficiency, Chronic heart failure, Heart failure metabolism, Multiple hormonal deficiency syndrome, Registry, Aged, Biomarkers, Chronic Disease, Deficiency Diseases, Disease Progression, Female, Heart Failure, Humans, Italy, Metabolic Diseases, Middle Aged, Internal Medicine, Emergency Medicine, Human, medicine.medical_specialty, Anabolic deficiency, Chronic heart failure, Heart failure metabolism, Multiple hormonal deficiency syndrome, Registry, Socio-culturale, 03 medical and health sciences, Internal medicine, business.industry, Settore MED/13 - ENDOCRINOLOGIA, Biomarker, medicine.disease, Metabolic Disease, Prospective Studie, Heart failure, Observational study, Hormone therapy, business
Abstract: Recent evidence supports the concept that progression of chronic heart failure (CHF) depends upon an imbalance of catabolic forces over the anabolic drive. In this regard, multiple hormonal deficiency syndrome (MHDS) significantly has impacts upon CHF progression, and is associated with a worse clinical status and increased mortality. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Therapy in Heart Failure) Registry (clinicaltrial.gov = NCT02335801) tests the hypothesis that anabolic deficiencies reduce survival in a large population of mild-to-moderate CHF patients. The T.O.S.CA. Registry is a prospective multicenter observational study coordinated by “Federico II” University of Naples, and involves 19 centers situated throughout Italy. Thyroid hormones, insulin-like growth factor-1, total testosterone, dehydroepiandrosterone , and insulin are measured at baseline and every year for a patient-average follow-up of 3years. Subjects with CHF are divided into two groups: patients with one or no anabolic deficiency, and patients with two or more anabolic deficiencies at baseline. The primary endpoint is the composite of all-cause mortality and cardiovascular hospitalization. Secondary endpoints include the composite of all-cause mortality and hospitalization, the composite of cardiovascular mortality and cardiovascular hospitalization, and change of VO 2 peak. Patient enrollment started in April 2013, and was completed in July 2017. Demographics and main clinical characteristics of enrolled patients are provided in this article. Detailed cross-sectional results will be available in late 2018. The T.O.S.CA. Registry represents the most robust prospective observational trial on MHDS in the field of CHF. The study findings will advance our knowledge with regard to the intimate mechanisms of CHF progression and hopefully pave the way for future randomized clinical trials of single or multiple hormonal replacement therapies in CHF.
Published: 2017

40. Low testosterone levels are associated with coronary artery disease in male patients with angina

Author: Rosano, G M C, Sheiban, I, Massaro, R, Pagnotta, P, Marazzi, G, Vitale, C, Mercuro, G, Volterrani, M, Aversa, A, and Fini, M
Published: 2007
Full Text: View/download PDF

41. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure

Author: Seferović, P.M. Coats, A.J.S. Ponikowski, P. Filippatos, G. Huelsmann, M. Jhund, P.S. Polovina, M.M. Komajda, M. Seferović, J. Sari, I. Cosentino, F. Ambrosio, G. Metra, M. Piepoli, M. Chioncel, O. Lund, L.H. Thum, T. De Boer, R.A. Mullens, W. Lopatin, Y. Volterrani, M. Hill, L. Bauersachs, J. Lyon, A. Petrie, M.C. Anker, S. Rosano, G.M.C.
Abstract: Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and associated with considerable morbidity and mortality. Significant advances have recently occurred in the treatment of T2DM, with evidence of several new glucose-lowering medications showing either neutral or beneficial cardiovascular effects. However, some of these agents have safety characteristics with strong practical implications in HF [i.e. dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RA), and sodium–glucose co-transporter type 2 (SGLT-2) inhibitors]. Regarding safety of DPP-4 inhibitors, saxagliptin is not recommended in HF because of a greater risk of HF hospitalisation. There is no compelling evidence of excess HF risk with the other DPP-4 inhibitors. GLP-1 RAs have an overall neutral effect on HF outcomes. However, a signal of harm suggested in two small trials of liraglutide in patients with reduced ejection fraction indicates that their role remains to be defined in established HF. SGLT-2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) have shown a consistent reduction in the risk of HF hospitalisation regardless of baseline cardiovascular risk or history of HF. Accordingly, SGLT-2 inhibitors could be recommended to prevent HF hospitalisation in patients with T2DM and established cardiovascular disease or with multiple risk factors. The recently completed trial with dapagliflozin has shown a significant reduction in cardiovascular mortality and HF events in patients with HF and reduced ejection fraction, with or without T2DM. Several ongoing trials will assess whether the results observed with dapagliflozin could be extended to other SGLT-2 inhibitors in the treatment of HF, with either preserved or reduced ejection fraction, regardless of the presence of T2DM. This position paper aims to summarise relevant clinical trial evidence concerning the role and safety of new glucose-lowering therapies in patients with HF. © 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology
Published: 2020

42. P286 Inverse relation between systolic blood pressure variability and global longitudinal strain in patients with Parkinson's disease and autonomic dysfunction

Author: S Selli, Volterrani M, V D\\'antoni, M Torti, P Grassini, L Vacca, V Morsella, and Caminiti G
Subjects: medicine.medical_specialty, Ejection fraction, Ambulatory blood pressure, Parkinson's disease, Longitudinal strain, business.industry, General Medicine, medicine.disease, Blood pressure, Internal medicine, Cardiology, Medicine, Radiology, Nuclear Medicine and imaging, Blood pressure monitoring, In patient, Systole, Cardiology and Cardiovascular Medicine, business
Abstract: Background Parkinson"s disease (PD) patients often present cardiac blood pressure (BP) derangement as a result of autonomic dysfunction. However their echocardiography pattern have been poorly investigated yet . Study aim: to evaluate the correlation between indices of left ventricular function ad 24/h blood pressure pattern in patients with PD Methods We evaluated 20 patients with diagnosed PD and autonomic dysfunction and 15 hypertensive age-matched subjects. All patients performed 24/h blood pressure monitoring (ABPM) and echocardiography. Left ventricular systolic function was evaluated through ejection fraction (EF), tissue doppler S wave and global longitudinal strain (GLS). BP variability (BPV) was evaluated through average real variability. Results GLS (17.6 vs 22.8; p = 0.04) was reduced in the PD group compared to hypertensive patients. Conversely EF and S wave was similar between the two groups. Patients with PD had an inverse significant correlation between GLS and 24/h systolic BPV (r= -0.64; p = 0.003) and a trend through significance between S wave and systolic BPV (r= -0.31; p = 0.07). sNocturnal diastolic BP was inversely related to GLS (r= -0.44; p = 0.001) . There were no correlation between GLS and BPV and values in hypertensive patients. Conclusions In PD patients GLS is related to indices of poor BP control. GLS appears to be an early detector of LV dysfunction in patients with PD and autonomic dysfunction.
Published: 2020

43. CARBON DIOXIDE AND METHANE EMISSIONS BY URBAN TURFGRASSES UNDER DIFFERENT NITROGEN RATES: A COMPARISON BETWEEN TALL FESCUE (FESTUCA ARUNDINACEA SCHREB.) AND HYBRID BERMUDAGRASS (CYNODON DACTYLON [L.] PERS. VAR. DACTYLON X CYNODON TRANSVAALENSIS BURTT-DAVY)

Author: BRANDANI, G., primary, BALDI, A., additional, CATUREGLI, L., additional, GAETANI, M., additional, GROSSI, N., additional, MAGNI, S., additional, PARDINI, A., additional, VOLTERRANI, M., additional, ORLANDINI, S., additional, and VERDI, L., additional
Published: 2021
Full Text: View/download PDF

44. Preliminary observations on the effects of acute infusion of growth hormone on coronary vasculature and on myocardial function and energetics of an isolated and blood-perfused heart

Author: Lorusso, Roberto, Pasini, E., Cargnoni, A., Ceconi, C., Volterrani, M., Burattin, A., Valle, D., Ferrari, R., and Giustina, A.
Published: 2003
Full Text: View/download PDF

45. Effects of testosterone on the Q-T Interval in older men and older women with chronic heart failure

Author: Schwartz, J. B., Volterrani, M., Caminiti, G., Marazzi, G., Fini, M., Rosano, G. M. C., and Iellamo, F.
Published: 2011
Full Text: View/download PDF

46. Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study

Author: Stocchi, F., primary, Vacca, L., additional, Grassini, P., additional, Tomino, C., additional, Caminiti, G., additional, Casali, M., additional, D'Antoni, V., additional, Volterrani, M., additional, and Torti, M., additional
Published: 2020
Full Text: View/download PDF

47. Correlation Between Systolic Blood Pressure Variability and Global Longitudinal Strain in Patients with Parkinson's Disease and Dysautonomia

Author: Caminiti G, Caminiti, primary, D Antoni V, D Antoni, additional, Morsella V, Morsella, additional, Torti M, Torti, additional, Grassini P, Grassini, additional, Vacca L, Vacca, additional, Stocchi F, Stocchi, additional, Selli S, Selli, additional, and Volterrani M, Volterrani, additional
Published: 2020
Full Text: View/download PDF

48. P286 Inverse relation between systolic blood pressure variability and global longitudinal strain in patients with Parkinson"s disease and autonomic dysfunction

Author: Caminiti, G, primary, D"antoni, V, additional, Morsella, V, additional, Torti, M, additional, Grassini, P, additional, Vacca, L, additional, Selli, S, additional, and Volterrani, M, additional
Published: 2020
Full Text: View/download PDF

49. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs

Author: Gori, M, Volterrani, M, Piepoli, M, Senni, M, Gori M, Volterrani M, Piepoli M, Senni M, Gori, M, Volterrani, M, Piepoli, M, Senni, M, Gori M, Volterrani M, Piepoli M, and Senni M
Abstract: Sacubritil ∗ valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor–neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.
Published: 2017

50. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition

Author: Volterrani, M, Iellamo, F, Senni, M, Piepoli, Mf, Volterrani M, Iellamo F, Senni M, MF, Volterrani, M, Iellamo, F, Senni, M, Piepoli, Mf, Volterrani M, Iellamo F, Senni M, and MF
Abstract: In heart failure, in addition to the renin–angiotensin–aldosterone system and sympathetic nervous system, the natriuretic peptide (NP) system plays a fundamental role among compensating mechanisms. The NPs undergo rapid enzymatic degradation that limits their vasorelaxant, natriuretic, and diuretic actions. Degradation of NPs is partially due to the action of neprilysin, which is a membrane-bound endopeptidase found in many tissues. This article summarizes recent findings on a new natriuretic peptide-enhancing drug and their implication for future pharmacological treatment of patients suffering from heart failure with reduced ejection fraction.
Published: 2017

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

641 results on '"Volterrani, M"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources